Age-specific progression of nigrostriatal dysfunction in Parkinson's disease

Raúl De La Fuente-Fernández, Michael Schulzer, Lisa Kuramoto, Jacquelyn Cragg, Nandhagopal Ramachandiran, Wing L. Au, Edwin Mak, Jess McKenzie, Siobhan McCormick, Vesna Sossi, Thomas J. Ruth, Chong S. Lee, Donald B. Calne, A. Jon Stoessl

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Objective: To investigate in vivo the impact of age on nigrostriatal dopamine dysfunction in Parkinson's disease (PD). Methods: PD patients (n = 78) and healthy control subjects (n = 35) underwent longitudinal positron emission tomography assessments using 3 presynaptic dopamine markers: (1) [ 11C](±)dihydrotetrabenazine (DTBZ), to estimate the density of the vesicular monoamine transporter type 2; (2) [11C]d-threo- methylphenidate, to estimate the density of the plasma membrane dopamine transporter; and (3) 6-[18F]-fluoro-L-dopa, to estimate the activity of the enzyme dopa-decarboxylase. Results: The study comprised 438 PD scans and 241 control scans (679 scans in total). At symptom onset, the loss of putamen DTBZ binding was substantially greater in younger compared to older PD patients (p = 0.015). Remarkably, however, the rate of progression of DTBZ binding loss was significantly slower in younger patients (p <0.05). The estimated presymptomatic phase of the disease spanned more than 2 decades in younger patients, compared to 1 decade in older patients. Interpretation: Our results suggest that, compared to older patients, younger PD patients progress more slowly and are able to endure more damage to the dopaminergic system before the first motor symptoms appear. These observations suggest that younger PD patients have more efficient compensatory mechanisms.

Original languageEnglish
Pages (from-to)803-810
Number of pages8
JournalAnnals of Neurology
Volume69
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Parkinson Disease
Dopamine
Vesicular Monoamine Transport Proteins
Dopa Decarboxylase
Asymptomatic Diseases
Dopamine Plasma Membrane Transport Proteins
Methylphenidate
Membrane Transport Proteins
Putamen
Levodopa
Positron-Emission Tomography
Healthy Volunteers
Cell Membrane
Enzymes
dihydrotetrabenazine

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

De La Fuente-Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., ... Stoessl, A. J. (2011). Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology, 69(5), 803-810. https://doi.org/10.1002/ana.22284

Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. / De La Fuente-Fernández, Raúl; Schulzer, Michael; Kuramoto, Lisa; Cragg, Jacquelyn; Ramachandiran, Nandhagopal; Au, Wing L.; Mak, Edwin; McKenzie, Jess; McCormick, Siobhan; Sossi, Vesna; Ruth, Thomas J.; Lee, Chong S.; Calne, Donald B.; Stoessl, A. Jon.

In: Annals of Neurology, Vol. 69, No. 5, 05.2011, p. 803-810.

Research output: Contribution to journalArticle

De La Fuente-Fernández, R, Schulzer, M, Kuramoto, L, Cragg, J, Ramachandiran, N, Au, WL, Mak, E, McKenzie, J, McCormick, S, Sossi, V, Ruth, TJ, Lee, CS, Calne, DB & Stoessl, AJ 2011, 'Age-specific progression of nigrostriatal dysfunction in Parkinson's disease', Annals of Neurology, vol. 69, no. 5, pp. 803-810. https://doi.org/10.1002/ana.22284
De La Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology. 2011 May;69(5):803-810. https://doi.org/10.1002/ana.22284
De La Fuente-Fernández, Raúl ; Schulzer, Michael ; Kuramoto, Lisa ; Cragg, Jacquelyn ; Ramachandiran, Nandhagopal ; Au, Wing L. ; Mak, Edwin ; McKenzie, Jess ; McCormick, Siobhan ; Sossi, Vesna ; Ruth, Thomas J. ; Lee, Chong S. ; Calne, Donald B. ; Stoessl, A. Jon. / Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. In: Annals of Neurology. 2011 ; Vol. 69, No. 5. pp. 803-810.
@article{44a6dbb8dd6b4bfa9413c3f6e14a409d,
title = "Age-specific progression of nigrostriatal dysfunction in Parkinson's disease",
abstract = "Objective: To investigate in vivo the impact of age on nigrostriatal dopamine dysfunction in Parkinson's disease (PD). Methods: PD patients (n = 78) and healthy control subjects (n = 35) underwent longitudinal positron emission tomography assessments using 3 presynaptic dopamine markers: (1) [ 11C](±)dihydrotetrabenazine (DTBZ), to estimate the density of the vesicular monoamine transporter type 2; (2) [11C]d-threo- methylphenidate, to estimate the density of the plasma membrane dopamine transporter; and (3) 6-[18F]-fluoro-L-dopa, to estimate the activity of the enzyme dopa-decarboxylase. Results: The study comprised 438 PD scans and 241 control scans (679 scans in total). At symptom onset, the loss of putamen DTBZ binding was substantially greater in younger compared to older PD patients (p = 0.015). Remarkably, however, the rate of progression of DTBZ binding loss was significantly slower in younger patients (p <0.05). The estimated presymptomatic phase of the disease spanned more than 2 decades in younger patients, compared to 1 decade in older patients. Interpretation: Our results suggest that, compared to older patients, younger PD patients progress more slowly and are able to endure more damage to the dopaminergic system before the first motor symptoms appear. These observations suggest that younger PD patients have more efficient compensatory mechanisms.",
author = "{De La Fuente-Fern{\'a}ndez}, Ra{\'u}l and Michael Schulzer and Lisa Kuramoto and Jacquelyn Cragg and Nandhagopal Ramachandiran and Au, {Wing L.} and Edwin Mak and Jess McKenzie and Siobhan McCormick and Vesna Sossi and Ruth, {Thomas J.} and Lee, {Chong S.} and Calne, {Donald B.} and Stoessl, {A. Jon}",
year = "2011",
month = "5",
doi = "10.1002/ana.22284",
language = "English",
volume = "69",
pages = "803--810",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Age-specific progression of nigrostriatal dysfunction in Parkinson's disease

AU - De La Fuente-Fernández, Raúl

AU - Schulzer, Michael

AU - Kuramoto, Lisa

AU - Cragg, Jacquelyn

AU - Ramachandiran, Nandhagopal

AU - Au, Wing L.

AU - Mak, Edwin

AU - McKenzie, Jess

AU - McCormick, Siobhan

AU - Sossi, Vesna

AU - Ruth, Thomas J.

AU - Lee, Chong S.

AU - Calne, Donald B.

AU - Stoessl, A. Jon

PY - 2011/5

Y1 - 2011/5

N2 - Objective: To investigate in vivo the impact of age on nigrostriatal dopamine dysfunction in Parkinson's disease (PD). Methods: PD patients (n = 78) and healthy control subjects (n = 35) underwent longitudinal positron emission tomography assessments using 3 presynaptic dopamine markers: (1) [ 11C](±)dihydrotetrabenazine (DTBZ), to estimate the density of the vesicular monoamine transporter type 2; (2) [11C]d-threo- methylphenidate, to estimate the density of the plasma membrane dopamine transporter; and (3) 6-[18F]-fluoro-L-dopa, to estimate the activity of the enzyme dopa-decarboxylase. Results: The study comprised 438 PD scans and 241 control scans (679 scans in total). At symptom onset, the loss of putamen DTBZ binding was substantially greater in younger compared to older PD patients (p = 0.015). Remarkably, however, the rate of progression of DTBZ binding loss was significantly slower in younger patients (p <0.05). The estimated presymptomatic phase of the disease spanned more than 2 decades in younger patients, compared to 1 decade in older patients. Interpretation: Our results suggest that, compared to older patients, younger PD patients progress more slowly and are able to endure more damage to the dopaminergic system before the first motor symptoms appear. These observations suggest that younger PD patients have more efficient compensatory mechanisms.

AB - Objective: To investigate in vivo the impact of age on nigrostriatal dopamine dysfunction in Parkinson's disease (PD). Methods: PD patients (n = 78) and healthy control subjects (n = 35) underwent longitudinal positron emission tomography assessments using 3 presynaptic dopamine markers: (1) [ 11C](±)dihydrotetrabenazine (DTBZ), to estimate the density of the vesicular monoamine transporter type 2; (2) [11C]d-threo- methylphenidate, to estimate the density of the plasma membrane dopamine transporter; and (3) 6-[18F]-fluoro-L-dopa, to estimate the activity of the enzyme dopa-decarboxylase. Results: The study comprised 438 PD scans and 241 control scans (679 scans in total). At symptom onset, the loss of putamen DTBZ binding was substantially greater in younger compared to older PD patients (p = 0.015). Remarkably, however, the rate of progression of DTBZ binding loss was significantly slower in younger patients (p <0.05). The estimated presymptomatic phase of the disease spanned more than 2 decades in younger patients, compared to 1 decade in older patients. Interpretation: Our results suggest that, compared to older patients, younger PD patients progress more slowly and are able to endure more damage to the dopaminergic system before the first motor symptoms appear. These observations suggest that younger PD patients have more efficient compensatory mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=79955466566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955466566&partnerID=8YFLogxK

U2 - 10.1002/ana.22284

DO - 10.1002/ana.22284

M3 - Article

VL - 69

SP - 803

EP - 810

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 5

ER -